Ligand Pharmaceuticals (LGND) Debt Ratio (2011 - 2026)

Ligand Pharmaceuticals' (LGND) quarterly Debt Ratio came in at 0.29 in Q1 2026, up 2.02% quarter-over-quarter from 0.29 in Q4 2025.

Ligand Pharmaceuticals (LGND) Debt Ratio (2011 - 2026) Analysis & Trends

Ligand Pharmaceuticals has disclosed Debt Ratio across 13 years of filings, most recently posting 0.29 for Q1 2026.

Debt Ratio for Q1 2026 came in at 0.29, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 0.29 (changed N/A YoY), and the FY2025 annual result was 0.29, changed N/A from the prior year.
Debt Ratio came in at 0.29 for Q1 2026 at Ligand Pharmaceuticals, up from 0.29 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.3 in Q3 2025 to a low of 0.07 in Q3 2022.
The 4-year median for Debt Ratio is 0.11 (2022), against an average of 0.18.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.18
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Ligand Pharmaceuticals	5.47 Bn	4.69 Bn	48.45 Mn	0.29

Download Data